Gastrointestinal Stromal Tumors News and Research

RSS
Imatinib improves RFS, overall survival in GIST patients after surgery

Imatinib improves RFS, overall survival in GIST patients after surgery

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Immune system may play a role in cancer therapies: Study

Immune system may play a role in cancer therapies: Study

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

ESMO releases revised set of clinical guidelines for cancer patient care

ESMO releases revised set of clinical guidelines for cancer patient care

Researchers evaluate outcomes of SD and PD in patients with GISTs

Researchers evaluate outcomes of SD and PD in patients with GISTs

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Minimal improvements made in survival rates of AYA population with cancer

Minimal improvements made in survival rates of AYA population with cancer

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST